Abstract Hereditary spastic paraplegia (HSP) is a syndrome designation describing inherited disorders in which lower extremity weakness and spasticity are the predominant symptoms. There are more than 50 genetic types of HSP. HSP affects individuals of diverse ethnic groups with prevalence estimates ranging from 1.2 to 9.6 per 100,000.
Introduction
''Hereditary spastic paraplegia'' (HSP) is a clinical diagnostic designation for those neurologic syndromes (a) in which bilateral lower extremity weakness and spasticity (each of variable degree) are the predominant (but often not only) manifestations; and (b) for which gene mutation is the major causative factor. Because with all classifications of clinical syndromes, it may be problematic to decide if a given disorder should be included or excluded in the category of HSP. For example, whereas paraplegin gene mutation, in which spastic paraparesis is often associated with ataxia, is recognized as a form of HSP (SPG7), Friedreich's ataxia and Charlevoix-Saguenay, syndromes in which ataxia is often associated with corticospinal tract deficits are considered forms of spinocerebellar ataxia and not forms of HSP. Although distal axon degeneration of corticospinal tracts is often reported in postmortem examination of HSP (discussed below), classification of a given clinico-genetic syndrome as a form of HSP is based on the clinical and genetic features rather than neuropathologic features.
There are more than 50 genetic types of HSP (Table 1) . Most types of HSP are designated by their genetic loci (''Spastic parapleGia'' [SPG] 1-56) that are numbered in order of their discovery. As with other large groups of genetically heterogeneous disorders, variation in the severity of the principle syndrome elements (lower extremity spasticity and weakness) together with the variable presence of additional neurologic (and occasionally systemic) abnormalities create wide clinical variation between (and within) genetic types of HSP. Nonetheless, by definition, clinical syndromes of HSP are characterized by lower extremity spasticity and weakness, each of varying degree, variable age-of-symptom onset, and variable degree of progression.
Clinical classification
HSP syndromes are classified clinically [94] as ''uncomplicated'' (characterized by lower extremity spasticity and weakness and subtle lower extremity dorsal column impairment); and ''complicated'' (in which spastic paraplegia is associated with additional neurologic or systemic abnormalities including dementia, ataxia, mental retardation, neuropathy, distal wasting, loss of vision, epilepsy, or ichthyosis [Sjogren-Larsson syndrome]). Although some genetic types of HSP usually (but not invariantly) manifest as ''uncomplicated'' (e.g.SPG4 HSP due to spastin gene mutation, the single most common form of autosomal dominant HSP), other genetic types usually (but not always) manifest as ''complicated'' HSP syndromes (such as SPG11 HSP, a common autosomal recessive form of HSP frequently associated with mental retardation and thin corpus callosum).
There is imperfect correlation between clinical classification (''uncomplicated'' versus ''complicated'') and genetic types of HSP. Restated, many genetic types of HSP are associated with both ''uncomplicated'' and ''complicated'' HSP syndromes. For example, SPG4 HSP, initially considered to be prototypical of uncomplicated HSP, has been associated with mental retardation and dementia [45, 190, 224, 235] , ataxia [163] , thin corpus callosum [168] , and muscle wasting [152, 169] . Similarly, SPG3A, which usually manifests as childhood onset, uncomplicated autosomal dominant HSP, has been associated with motorsensory axonal neuropathy, distal wasting, and thin corpus callosum [55, 87, 112, 170] . Conversely, although autosomal recessive SPG7 (paraplegin mutation) and SPG11 (spatacsin mutation) usually manifest as ''complicated HSP syndromes'' (with ataxia being frequent in SPG7 HSP and mental retardation being frequent in SPG11 HSP), both of these types of HSP may also manifest as ''uncomplicated'' spastic paraplegia syndromes.
Some clinical variability within a given genetic type of HSP may be due to the variable consequences of discrete gene mutation (''genotype-phenotype correlation''), about which very little is known in HSP. In some cases, however, both ''uncomplicated'' and ''complicated'' syndromes occur in the same family in which individuals have the identical gene mutation. These examples highlight the influence of as-yet-unidentified ''modifying factors'' (including genes and potentially environmental factors) in determining the phenotype.
Clinical presentation
For the vast majority of individuals, HSP presents with gait impairment due to lower extremity weakness and spasticity. Urinary urgency is common in HSP and occasionally may be an early or presenting feature. Symptoms may be first evident at any age, from early childhood through senescence. In general, subjects with ''uncomplicated'' HSP have normal life expectancy and do not experience loss of dexterity, strength, or coordination in the upper extremities, dysarthria or dysphagia.
Lower extremity spastic weakness (each of variable degree), combined with variable presence of one or more complicating features (discussed above) create numerous clinical HSP syndromes. The following HSP syndromes are commonly recognized (Table 2 [75] ): (1) uncomplicated HSP; (2) spastic paraplegia associated with peripheral motor neuropathy and/or distal wasting; (3) spastic paraplegia associated with cognitive impairment; (4) spastic paraplegia associated with ataxia; (5) spastic paraplegia associated with neuroimaging abnormality; (6) spastic paraplegia associated with additional neurologic and systemic abnormalities. Examples of complicated HSP syndromes are summarized in Table 2 .
The age-of-symptom onset may be quite variable even with a given genetic type of HSP. Although the average age-of-symptom onset of some genetic types of HSP is much younger (e.g. childhood onset in SPG3A) than in other types (e.g. late-teenage to adult onset in SPG6 HSP), significant overlap between the range of ages at which symptoms first begin limits the ability to predict the genetic type of HSP from age-of-symptom onset alone.
Progression (rate and degree with which functional disability increases) in HSP is quite variable, including relatively static, non-worsening disability, inexorable worsening, and, after a period of insidious decline, reaching an apparent stabilization of disability (apparent [212, 217] ''functional plateau''). The fact that many HSP subjects seem to reach a functional plateau beyond which there is very little further disability (beyond that which is attributed to and parallels the approximate rate of normal, age-related decline) may reflect the interplay of multiple factors including (a) reduced rate of neurodegeneration; and (b) disease-ameliorating processes that promote recovery of damaged axons; and (c) functional compensation through neuroplasticity. When HSP begins in early childhood (first evident as toe-walking by age 2 years, for example), symptoms may be relatively non-progressive even over several decades. This is ''relatively non-progressive course'' is typical (but not invariant) of SPG3A HSP (the most common cause of early childhood onset, autosomal dominant HSP) but may in addition be seen in SPG4 HSP and other types [31, 56] . The syndrome of early childhood onset, relatively nonprogressive HSP may be extremely similar to that of spastic diplegic cerebral palsy. Indeed, HSP gene mutations (including de novo mutation for autosomal dominant HSP) have been identified in subjects initially diagnosed as having cerebral palsy [61, 155, 165, 184] . It may be appropriate to consider the recently identified genetic loci for autosomal recessive spastic diplegic cerebral palsy as a form of very early onset HSP [149, 238] .
The rate and extent of clinical worsening in HSP is quite variable. For many individuals, gait impairment worsens insidiously over many years. The rate of clinical progression may not be uniform, however. Both more rapid progression during adolescence and slower rate of worsening after 5-10 years of symptoms are not uncommon. As noted above, many individuals, after 5-10 years of worsening gait impairment, appear to reach a ''functional plateau'' after which the rate of worsening seems to be reduced.
There are at least four examples in which HSP gene mutations were associated with clinical syndromes other than HSP. First, SPG3A/atlastin mutation (which typically causes early childhood onset, relatively non-progressive, uncomplicated HSP) was recently identified in a family with autosomal dominant Hereditary Sensory Neuropathy (HSN 1) rather than with the syndrome of HSP [86] . In addition to profound, an early sensory loss often associated with painless injuries, impaired healing, and osteomyelitis, HSN1 may be associated with distal motor involvement in advanced cases [86] .
Second, BSCL2/Seipin mutations, when heterozygous, cause both autosomal dominant HSP (SPG17), CharcotMarie-Tooth type 2, and distal hereditary motor neuropathy type V. When homozygous, BSCL2/Seipin mutations cause, congenital generalized lipodystrophy type 2 (CGL2), manifesting as severe lipoatrophy, insulin resistance, hypertriglyceridemia, and mental retardation [110, 140] .
Third, although SPG11/spatacsin mutations are a frequent cause of autosomal recessive HSP (often, but not invariably associated with thin corpus callosum and mental retardation), they have also presented as levodoparesponsive, juvenile Parkinsonism [12, 153] .
And finally, although mutation of the SPG20/spartin gene causes autosomal recessive HSP associated with distal muscle wasting (Troyer syndrome), hypermethylation of the SPG20/spartin promoter is an apparent biomarker of colorectal carcinoma [134] .
Neurologic examination
Neurologic examination of subjects with uncomplicated HSP demonstrates variable degrees of lower extremity spasticity and weakness. Spasticity is greatest in hamstring, quadriceps, adductor, and gastrocnemius-soleus muscles. Weakness is the most prominent in iliopsoas, hamstring, and tibialis anterior muscles. Hypperreflexia, crossed adductor signs, extensor plantar responses are typically present (plantar responses may occasionally be absent). Vibration sensation in the toes is frequently mildly impaired. Mild upper extremity hyperreflexia, without increased muscle tone, weakness, or impaired dexterity is common in subjects with uncomplicated HSP. Although pes cavus is frequent in HSP, it may be absent even in clearly affected subjects. In addition to variable degrees of lower extremity weakness and spasticity and mild decrease in distal vibration sensation, neurologic examination of subjects with ''complicated'' HSP syndromes demonstrates additional neurologic or systemic abnormalities, such as cognitive impairment, dementia, optic neuropathy, retinitis pigmentosa, extrapyramidal disturbance, ataxia, peripheral neuropathy, distal wasting, or cataracts.
The degree to which muscle weakness and muscle spasticity contribute to functional gait impairment may be quite variable between individuals [94] . Some individuals have no significant weakness, with gait disturbance resulting primarily from spasticity and slowness of movements. For these individuals, medications that reduce spasticity may be beneficial. For other individuals, muscle weakness is a significant factor in gait disturbance. For individuals with significant weakness, muscle relaxing medications (including Botulinum toxin injections and intrathecal Lioresal pump) offer much less functional improvement. 
Genetic classification
There are dominant, recessive, and X-linked forms of HSP, each of which is genetically heterogeneous. In addition, mitochondrial ATP6 mutation is an example of a spastic paraplegia syndrome that is transmitted by maternal inheritance [230] . HSP genetic loci are designated SPG (''SPastic parapleGia'') 1-56 in order of their discovery.
There also are inherited disorders in which lower extremity spastic weakness is the primary clinical symptom that do not have ''SPG'' designations (e.g. SPOAN syndrome, Epsilon subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct5), and mitochondrial ATP6 gene mutation (Table 1) . At least one form of HSP may manifest as both an autosomal recessive and autosomal dominant disorder. SPG7 HSP was originally described as an autosomal recessive disorder due to homozygous or compound heterozygous SPG7/paraplegin gene mutations. Subsequently, there are reports of complicated and uncomplicated HSP syndromes associated with heterozygous SPG7 paraplegin mutation [15, 42, 148] . Some of these individuals have similar histologic features (e.g. ragged red fibers in skeletal muscle biopsy) or biochemical evidence of mitochondrial disturbance similar to that shown in subjects with homozygous (or compound heterozygous SPG7/paraplegin mutations) [42] . It is not known whether autosomal recessive versus autosomal dominant transmission is associated with specific SPG7 mutations. Nor is it known if other types of recessively inherited HSP may also manifest as autosomal dominant disorders. Nonetheless, the fact that SPG7 HSP may manifest as both a dominantly inherited and recessively inherited disorder has significant implications for genetic counseling.
Genetic counseling
Genetic counseling in HSP must consider the often marked phenotypic variation (including age-of-symptom onset, severity, and the presence of ''complicating feature'') between (and often within) different genetic types of HSP, and even between individuals in the same family, who share the identical HSP gene mutation. Genetic penetrance in autosomal dominant HSP is age-dependent, may be high (80-90 % in SPG4 HSP) or as low as 70 % [67] . Apparent genetic anticipation has been reported occasionally in SPG3A and SPG4 HSP [44, 164, 185, 186] . It is interesting that descriptions of apparent genetic mutation for which the causative SPG3A [155] or SPG4 HSP mutations were described did not include trinucleotide repeat (or other tandem nucleotide) expansions that have been associated with other instances of genetic anticipation (such as in Huntington's disease, myotonic dystrophy, and other disorders).
Caution must be exercised in providing genetic counseling and prognosis for many genetic types of HSP because the full phenotypic spectrum and genetic penetrance are often not fully known. This applies particularly to subjects from families for whom the genetic type is not known; and subjects with genetic types of HSP that have been described in only one or several families. With the exception of a minority of HSP types (notably SPG3A, SPG4, SPG7, and SPG11) in which dozens of affected subjects have been reported, clinical descriptions of the majority of genetic types of HSP are limited to one to several families. Moreover, very little is known about mutation-specific genetic penetrance and genotype-phenotype correlation of individual HSP gene mutations. Finally, particular caution should be used when counseling families with SPG7 HSP in light of the observation that some SPG7 may cause autosomal dominant or autosomal recessive HSP.
Neuropathology
Postmortem studies in HSP consistently report axon degeneration involving lateral corticospinal tracts that is most severe at the distal ends (in the thoracic spinal cord) and less severe in the cervical spinal cord [25, 43, 59, 93, 197, 204, 205, 237] . In addition to distal corticospinal tract degeneration, degeneration of axons in fasciculus gracilis fibers is observed consistently and is most prominent in the cervical spinal cord.
Spinal cord axon degeneration may be sufficient to cause mild to marked atrophy of cervical and thoracic segments [66, 97, 98, 126, 210] . In some instances, corticospinal tract degeneration has extended rostrally to include the pons, cerebral peduncles, medulla, and internal capsule. Decreased number of pyramidal (neurons (Betz cells) has been described. Demyelination of degenerating corticospinal tracts and fasciculus gracilis fibers is noted frequently and generally considered to be consistent with the degree of axon degeneration rather than signifying a primary demyelinating process.
Caution must be used when generalizing HSP neuropathology because (1) there have been very few autopsies in HSP most of which are from subjects for whom the genetic type of HSP is unknown (e.g. [129] ). Further, there may be a bias toward performing and reporting autopsies in unusual or complicated forms of HSP, such as those in which lifespan was reduced (e.g. [144, 166] ). For example, the postmortem findings of novel, crystalloid deposits containing oligodendroglial cytoskeletal elements (a-and b-tubulin and TPPP/p25) in a subject with apparently autosomal dominant hereditary spastic paraplegia (genetic type unknown) are of uncertain significance [244] .
A number of postmortem studies have been reported for subjects with possible or probable autosomal recessive spastic paraplegia, but for whom the specific type of HSP is not known. For example, Kuru et al. [129] reported a subject with probable autosomal recessive spastic paraplegia associated with thin corpus callosum. Pathologic findings included neurodegeneration involving corticospinal tract, thalamus, cerebral white matter and substantia nigra, anterior horn, and dorsal columns of the spinal cord. There was widespread neuronal lipofuscin and eosinophilic granules; and severe gliosis in the cerebral white matter and substantia nigra. Nomura et al. [166] reported a subject with probable autosomal recessive spastic tetraplegia, dysarthria, dementia, leading to death at age 50. Pathologic findings included severe brain atrophy, diffuse spongy changes, neuronal atrophy with lipofuscinosis, degeneration of dorsal spinocerebellar and corticospinal tracts, marked loss of anterior horn cells and nucleus gracilis neurons, and evidence of mitochondrial abnormality in skeletal muscle. Wakabayashi et al. [232] reported a subject with probable autosomal recessive spastic paraplegia associated with thin corpus callosum, sensory disturbance, and amyotrophy. Pathologic changes included neuronal loss and gliosis in upper and lower motor neuron pathways, thalamus, lateral geniculate body, dentate nucleus, and posterior column of the spinal cord; many remaining neurons contained ubiquitinated lipofuscin granules; and reduced number of pigmented neurons in the substantia nigra. It is difficult to know the extent to which one or more postmortem observations from individual cases of genetically undefined spastic paraplegia may be generalized to one or more types of spastic paraplegia of known genetic cause (genetically defined HSP).
Finally, because HSP usually does not shorten lifespan, HSP autopsies may disclose findings related to age or cooccurrence of unrelated, age-dependent disorders (such as Alzheimer's disease and Parkinsons disease). For example, postmortem [237] studies were reported in a subject with SPG4/spastin mutation, who in addition to progressive lower extremity spastic weakness, had dementia, facial bradykinesia and tremor. Corticospinal tract degeneration was maximal in thoracic and lumbar cord and associated with myelin pallor. In addition, the neuronal loss was noted in the hippocampus and entorhinal cortex. Frequent neurofibrillary tangles that were immunoreactive for tau were present in remaining neurons. Senile plaques were not observed. Granulovacuolar degeneration and ballooned neurons that immunostained strongly for tau and a-bcrystallin were prominent in limbic areas. The substantia nigra showed moderate loss of pigmented dopaminergic neurons and frequent Lewy bodies and pale bodies. Although these latter findings correlated with clinical Parkinsonism, it is not possible to determine whether the entirety of neuropathologic findings is attributable to SPG4/Spastin mutation. Murphy et al. [161] described an HSP subject with SPG4/spastin mutation subject, who had dementia and for whom postmortem findings included widespread ubiquitin positivity within the neocortex and white matter. These and similar reports illustrate the caution that must be exercised in assessing which postmortem findings in HSP subjects are the consequence of the HSP gene mutation and which findings are attributable to the effects of age and the occurrence of unrelated, age-associated disorders (or theoretically, a combination of these factors).
The predominant distribution of axon degeneration to the distal ends of cortical spinal tracts and fasciculus gracilis fibers has given rise to two widely held concepts: (1) HSP reflects particular vulnerability of the longest, motor and sensory axons in the central nervous system; and (2) that the HSP represents a primary axonopathy. Each of these generalizations is incomplete in the following regards.
First, it is increasingly recognized that neuropathology in many types of HSP extends beyond the corticospinal tracts, dorsal column fibers and even the central nervous system. For example, though formerly considered to represent ''uncomplicated'' HSP, approximately 17 % of subjects with SPG3A HSP have motor-sensory axonal peripheral neuropathy [112] . Peripheral neuropathy has been described as either a rare or common feature in more than a dozen genetic types of HSP (Table 2) .
Lower motor neuron involvement, evident as distal muscle wasting is common in a many genetic types of HSP (Table 1 , 2), notably those due to SPG10/KIF5A, SPG20/ Spartin, SPG39/NTE, SPG17/BSCL2 gene mutation. In subjects with SPG39 reflects distal motor neuropathy (not motor-sensory neuropathy). Lower motor neuron involvement may also occur in SPG11 HSP (many of whom conform to a clinical syndrome of juvenile ALS [167] ); and is a typical feature of SPG17 (Silver syndrome) and SPG20 (Troyer syndrome). Anterior horn cell abnormalities (hyaline inclusions, altered mitochondrial distribution, and altered immunostaining for cytoskeletal proteins [nonphosphorylated neurofilament protein and b-tubulin] were also observed [236] in postmortem studies in SPG4 HSP (the single most common form of dominantly inherited HSP which usually manifests as an uncomplicated spastic paraplegia syndrome.
Second, neurodegeneration in many types of HSP involves neurons that are not among the longest in the CNS (such as the occurrence of dementia in SPG4 HSP, ataxia in SPG7 HSP, and optic neuropathy in SPG7 HSP). For example, postmortem studies in a subjects with SPG4/ spastin mutation revealed variable involvement in cerebellum and basal ganglia, Clarke's column, and reduced number of anterior horn cells in some (but not all) subjects [237] .
Third, myelin abnormalities are more common in HSP than previously recognized. At least two types of HSP are due to mutations in genes that are expressed not in neurons, but rather in oligodendroglia (SPG2/proteolipid protein, SPG42/Connexin 47 mutation). Some mouse models of SPG2/proteolipid protein mutation HSP have axon degeneration (rather than demyelination), indicating that primary oligodendroglial abnormality may cause axonal degeneration. Postmortem study of a subject with late age-of-symptom onset SPG2 HSP demonstrated moderate cerebral atrophy, widespread pallor of central nervous system myelin preferentially affecting corticospinal tracts, and severe corticospinal tract axon degeneration [215] .
In addition to these forms of HSP in which the causative gene mutation is expressed in oligodendroglial, white matter abnormalities have been observed in many forms of complicated HSP (e.g. due SPG5/CYPB7, SPG7/Paraplegin, SPG21/Maspardin, and SPG35/FA2H gene mutations, see Table 1 ) [60, 63, 127, 208, 234, 250] . It is noteworthy that homozygous mutation of the bovine spastin gene causes congenital bovine dysmyelination [220] rather than primary axonal degeneration.
Fourth, some of the abnormalities in HSP may be developmental rather than degeneration. Vassilopoulos et al. [227] showed that the spinal canal diameter was smaller in subjects with HSP. This suggests disturbance in spinal canal development perhaps from altered induction of the developing spinal cord. Thin corpus callosum (associated most often with SPG11, but also may occur in SPG3A [170] , SPG4, SPG7, SPG15, SPG21, SPG32, SPG47, SPG49, SPG54, and SPG56 (see Table 1 ) is usually considered a developmental abnormality although Franca et al. [80] showed progressive corpus callosum thinning on serial brain magnetic resonance imaging. The analysis of the functions of HSP proteins indicates that a variety of primary molecular abnormalities underlie various genetic types of HSP (summarized in Fig. 1 ). These include (1) axonal transport abnormality, e.g. SPG30/KIF1A, SPG10/KIF5A [245] and possibly SPG4/ Spastin [119] ; (2) disturbance in ER morphology (e.g. SPG12/Reticulon 2, SPG3A/Atlastin, SPG4/Spastin, and SPG31/REEP1); (3) mitochondrial abnormality (e.g. SPG13/chaperonin 60/heat-shock protein 60 [92] , SPG7/ paraplegin; and mitochondrial ATP6 [18, 47, 73, 239] ; (4) Among the molecular and cellular categories disturbed in various forms of HSP, it is notable that a subset of HSP types is caused by disturbance in phospholipid, sphingolipid, and fatty acid metabolism (reviewed in Lamari et al. [130] ). For example DDHD1 (SPG28) and DDHD2 (SPG54) have phospholipase A1 activity and neuropathy target esterase (NTE, SPG39) is a phospholipase B (combined phospholipase A1 and A2 activity). In addition, mutation in a phospholipase A2 gene (PLA2G6) causes autosomal recessive infantile neuroaxonal dystrophy [121] associated with spastic tetraplegia, as well as complex neurodegeneration phenotypes associated with brain iron accumulation [128, 130] . CYP2U1 (SPG56) catalyzes hydroxylation of arachidonic acid and similar long-chain fatty acids [219] . Fatty acid amide hydroxylase (FA2H, SPG35) catalyzes 2-hydroxylation of myelin galactolipids, Acta Neuropathol (2013) 126:307-328 317 SPG10/KIF5A Kinesin heavy chain (KIF5A) a molecular motor subunit that participates in the intracellular movement of organelles and macromolecules [245] SPG11/Spatacsin Unknown function; spatacsin is a component of a protein complex that includes two other HSP proteins, SPG15/ZFYVE26 and SPG48/KIAA0415 [209] suggesting that these forms of HSP may share similar molecular pathogenesis. Interacts with SPG48/KIAA0415, SPG15/ ZfyVe26, C200RF29, DKFZp761E198
Analysis of HSP genes and their encoded proteins sheds light on the molecular mechanisms underlying HSP

HSP genes have been identified (summarized in
SPG12/RTN2 RTN2 gene encodes reticulon 2, an ER-shaping protein.
Reticulon interacts with SPG4/spastin [157] SPG13/HSPD1 HSPD1 gene encodes Chaperonin 60 (also known as heat-shock protein 60, HSP60), the large subunit of the mitochondrial Hsp60/Hsp10 chaperonin complex; functions in mitochondrial protein quality control (binding and sequestration, and refolding of unfolded proteins) [91] SPG15/Spastizin (ZFYVE26) FYVE-domain proteins have diverse functions including membrane trafficking, signal transduction, regulating the cytoskeleton, and serving as phosphatidylinositol 3-phosphate (PtdIns3P) phosphatases. Spastizin colocalizes with ER and endosome markers and is a component of a protein complex that includes two other HSP proteins, SPG11/spatacsin and SPG48/KIAA0415. Interacts with SPG11/Spatacsin and SPG48/KIAA0415 [89, 159, 209] SPG17/BSCL2 BSCL2/seipin: Endoplasmic reticulum transmembrane protein; mutations appear pathogenic through induction of endoplasmic reticulum stress-mediated apoptosis [109] [110] [111] SPG18/ERLIN2 ERLIN2 is a component of lipid rafts that localize to ER and nuclear membranes. ERLIN2 is a mediator of ER-stress response to protein misfolding 
SPG20/Spartin
Spartin: N-terminal region similar to spastin; homologous to proteins involved in the morphology and trafficking of endosomes; also localizes to mitochondria; interacts with Eps 15, a protein known to be involved in endocytosis and the control of cell proliferation, suggesting that spartin may be involved in endocytosis, vesicle trafficking, or mitogenic activity; spartin promoter hypermethylation is associated with cytokinesis arrest in colorectal carcinoma. Interacts with GRP78, GRP75, ubiquitin, and the E3 ubiquitin-protein ligases AIP4/Itch and AIP5/WWP1, and; nucleolar protein ''nucleolin''; inhibits BMP signaling [20, 106, 134, 136, 154, 221] SPG21/Maspardin Appears to be a cytosolic protein partitioned between the cytosol and vesicles of the endosomal/ trans-Golgi network; may play a role in endosomal trafficking; may be similar to a noncatalytic a/b hydrolase protein NDRG1, mutations in which cause peripheral neuropathy with early axonal involvement. Interacts with Aldehyde dehyrogenase ALDH16A1 [90, 208] SPG22/MCT8 Monocarboxylate transport 8 (MCT8) is a thyroid hormone transporter, results in elevated serum triiodothyronine (T3) levels [143] SPG28/DDHD1 DDHD1 is a phosphatidic acid-preferring phospholipase A1 (PA-PIA1). There is evidence that DDHD1 is involved in stimulus-dependent formation of arachidonic acid-containing lysophosphatidyl inositol which plays a role in signal transduction including that of GPR55, a G-protein coupled, putative canabinoid receptor [246] SPG30/KIF1A Microtubule-dependent motor protein (in kinesin-3 family) with apparent role as primary anterograde motor protein for axonal transport of dense-core vesicles [124, 135] SPG31/REEP1 Receptor expression enhancing protein 1 (REEP1), structurally related to the DP1/Yop1p family of endoplasmic reticulum-shaping proteins; required for ER network formation in vitro; forms complexes with atlastin and spastin within endoplasmic reticulum; also binds to microtubules and promotes ER alignment along the microtubule cytoskeleton in vitro. Interacts withSPG3A/Atlastin and SPG4/Spastin
SPG33/ZFYVE27 ZFYVE27/protrudin has a role in Rab-11-mediated membrane trafficking and promotes neurite outgrowth. Interacts with SPG4/Spastin and RAB11
[32, 142] SPG35/FA2H Fatty acid 2-hydroxylase (FA2H) in oligodendroglia catalyzes the 2-hydroxylation of myelin galactolipids, galactosylceramine, and sulfatide; and therefore, helps in determining myelin lipid content [83] SPG39/NTE Neuropathy target esterase (NTE) is a phospholipase B localized to ER membranes; may reduce cytotoxic lysophosphatidylcholine; implicated in toxic organophosphorus compound induced delayed neurodegeneration (OPIDN); may function to regulate cyclic AMP-dependent protein kinase. Interacts with cyclic AMP-dependent protein kinase (in Drosophila) [3, 17, 27, 65, 84, 85, 116, 117, 192, 231, 243, 247] SPG42/SLC33A1 SLC33A1 is an acetyl-CoA transporter that moves acetyl-CoA into the Golgi apparatus where it may be transferred to sialyl residues of gangliosides and glycoproteins [132] SPG43/C19orf12 Membrane protein of uncertain function SPG44/GJA12/GJC2 Gap junction protein (GJA12/GJC2) also known as connexin47 (Cx47); important factor in formation of specialized channels (''gap junctions'') between cells that allow selective movement of ions and metabolites between adjacent intracellular compartments [72, 172, 199] SPG47/AP4B1 Adaptor protein complexes (AP1, AP2, AP3, and AP4) are widely expressed, and evolutionarily conserved complexes that participate in vesicle formation and selective inclusion of specific proteins for these vesicles. Homozygous mutations in three AP4 proteins (AP4B1, AP4E1, AP4M1, AP4S1) were identified in subjects with somewhat diverse, autosomal recessive neurologic disorders that share neonatal hypotonia, spastic tetraplegia, marked cognitive impairment associated, and thin corpus callosum [1, 23, 58, 103, 104, 229] SPG48/KIAA0415 KIAA0415 encodes a putative helicase involved in DNA repair; Interacts with SPG11/ Spatacsin, SPG15/ZFYVE26, C20ORF29, DKFZp761E198. KIAA0415 0 s function as a subunit for adapter protein 5 (AP-5) suggests a role in endosome membrane dynamics [102, 103, 209] SPG49/TECPR2
Tectonin beta propeller repeat containing protein 2 (TECPR2) appears to participate in autophagy. TECPR2 binds to homologues of autophagy-related proteins (Atg8), including MAP1LC3; and upregulates autophagosome accumulation in vitro [26, 173] SPG50/AP4M1 (see AP4B1) [1, 23, 58, 104, 229] SPG51/AP4E1 (see AP4B1) SPG52/AP4S1 (see AP4B1) [58, 104] galactosylceramine, and sulfatide. Mutations in fatty acid aldehyde dehydrogenase (FALDH, Sjogren-Larsson syndrome) and fatty acid elongase (ELOVL4) each cause autosomal recessive syndromes in which icthyosis is associated with spastic quadriplegia [9, 57] . The mechanisms (such as the roles of altered lipid-mediated signal transduction or altered membrane rigidity/fluidity) by which these fatty acid and phospholipid disturbances are pathogenic are not clear.
The functional heterogeneity of HSP genes suggests that corticospinal tract axons (and those of dorsal column fibers to a lesser extent) are vulnerable to a number of distinct molecular disturbances. Identification of many HSP proteins, increasing insights into the functions of these proteins, and functional overlap between HSP protein subsets notwithstanding, attempts to integrate functionality of HSP proteins into a single underlying pathogenic mechanism for the myriad forms of HSP is considered both [131, 253] SPG54/DDHD2 DDHD2 (DDHD-domain-containing 2) is an intracellular phospholipase A 1 (iPLA 1 ). DDHD2 and related proteins (DDHD1 and SEC23IP) also appear to be involved organelle biogenesis and membrane trafficking [6, 109, 164, 165, 203, 206, 222] SPG56/CYP2U1 CYP2U1 can catalyze hydroxylation of arachidonic acid, eicosopentanoic acid, docoshexanoic acid and related long-chain fatty acids that mediate signal transduction pathways [219] CcT5 Epsilon subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct5); contributes to the protein folding and assembly of a wide variety of cytosolic proteins including actin and tubulin
[36]
Mitochondrial ATP6 gene Synthesis of ATP (from ADP) in mitochondria is coupled to translocation of protons from the mitochondrial matrix to specific intermembrane sites. Mitochondrial ATP6 forms a channel through which protons flow back from intermembrane sites into the mitochondrial matrix; and is thus an important factor in mitochondrial ATP production [147, 230] premature and overly simplistic. Although knowledge of HSP is expanding rapidly, there are nearly 20 HSP genes that have been genetically mapped, but not yet identified.
Moreover, rather than a single, common pathogenic mechanism underlying HSP, it appears likely that disturbance in a number of different molecular processes results in a pattern of relatively selective neurodegeneration involving the corticospinal tracts predominantly. In this regard, the HSPs may be similar to the amyotrophic lateral scleroses (plural), a heterogeneous group of motor neuron disorders in which a number of different underlying molecular processes (e.g. [179] ) have been implicated (including excitotoxic injury, glial abnormalities, RNA processing disturbance [14] , and protein misfolding, for example). For most HSP gene mutations, the extent to which axon degeneration is ''cell autonomous'' (due to intrinsic disturbances only in the neurons undergoing degeneration); or ''non-cell autonomous'' (in which an axon's degeneration depends on its interaction with other cells including glia) is unknown. As noted above, axon degeneration in SPG2 and SPG42 are due to gene mutations that are primarily expressed in oligodendroglia (e.g. proteolipid protein and GJA12/Connexin 47). This indicates that axon degeneration in these types of HSP is ''non-cell autonomous'' and illustrates the importance of oligodendroglia in axon maintenance.
Animal models of HSP
Animal models of HSP (reviewed in [75] and [183] ) include mouse, rat, Drosophila, zebrafish, C. elegans, and cattle. The ability to produce axon degeneration and agedependent motor impairment in animal models of HSP permits evaluation of genetic mechanisms (such as haploinsufficiency versus ''dominant negative'' effect) and explore pathogenic mechanisms and potential treatments. Several generalizations may be made. First, vertebrate and invertebrate animal models are useful for demonstrating ''proof of concept'' that an identified HSP gene mutation is pathogenic. Second, the behavioral phenotype (locomotor impairment) in mouse models of HSP (either spontaneous mutants such as ''rumpshaker'' model of SPG2 or gene knock-out models), is usually much more mild than humans with the same or equivalent mutations. Preliminary observations in a transgenic rat model of SPG6 mutation suggest that rats may exhibit more severe motor impairment than mice [122] . And finally, the occurrence of congenital dysmyelination in American Brown Swiss cattle that are homozygous for bovine spastin gene mutation [220] suggests that different pathology (demyelination in cattle versus axon degeneration in humans) may be related either to species-specific effects or the nature of the gene mutation (homozygous in cattle, heterozygous in humans).
An important use of HSP animal models will be to determine the extent to which an HSP gene mutation has cell-autonomous pathogenesis. For example, does axon degeneration result when haploinsufficiency is created only in neurons (using Cre-lox cell-type specific gene knockout, for example)? Studies of mouse models of ALS due to superoxide dismutase 1 (SOD1) gene mutation have highlighted the importance of glia-neuron interaction in determining the onset and rate of progression of neurodegeneration.
Conclusions
Rapid discovery of HSP genes and evaluation of their respective protein functions is reshaping our understanding of the HSPs. Nonetheless, a couple of general concepts remain. First, although lower extremity spastic weakness predominates the clinical syndrome, and is the primary factor in functional disability, it is important to note that HSP for the majority of subjects is a motor-sensory disorder. Although usually subtle, dorsal column impairment is common in most types of HSP. And second, axon degeneration particularly involving distal ends of long fibers in the central nervous system is a common pathologic feature. Beyond these concepts, much of our understanding of HSP is in a state of rapid evolution. For example, though previously considered to be a distal motor-sensory, axonopathy limited to the central nervous system, we now recognize that a majority of genetic forms of HSP involve peripheral neuropathy or other neurologic abnormalities in at least a subset of patients. The concept that HSP exclusively involves length-dependent distal axon degeneration is being modified in light of awareness that neurodegeneration may include shorter axons, including those in the cerebellum and those traversing the corpus callosum. And finally, the occurrence of HSP due to mutations in genes that are expressed primarily in oligodendroglia (proteolipid protein and connexin 47) highlights the ''non-cell autonomous'' pathogenesis of some forms of HSP; and the importance of neuron-glial interaction in axon maintenance and degeneration. The extreme genetic heterogeneity of HSP and the diverse functions of HSP proteins indicate that corticospinal tract axons (and dorsal column axons to a lesser extent) are vulnerable to a variety of primary metabolic impairments. Rather than reflecting disturbance of a single common biochemical pathway, it appears that the common clinical features (i.e. predominated by corticospinal tract degeneration) reflect the limited phenotypic manifestations from relatively uniform degeneration elicited by diverse molecular causes. These advances and the creation of animal and in vitro models permit direct exploration of HSP's pathophysiology and bring us closer to develop treatments for this group of disorders. 
